India's drug regulator identified 159 pharmaceutical samples as substandard and one as spurious during May inspections. The findings highlight ongoing quality concerns in the country's medicine supply chain. Authorities will enforce corrective actions to protect public health and prevent unsafe drugs from reaching consumers. The move underscores the regulator's vigilance in safeguarding drug safety.
India's drug regulator identified 159 pharmaceutical samples as substandard and one as spurious during May inspections. The findings highlight ongoing quality concerns in the country's medicine supply chain. Authorities will enforce corrective actions to protect public health and prevent unsafe drugs from reaching consumers. The move underscores the regulator's vigilance in safeguarding drug safety.